GRANULES stock news on Anadi Algo News

Monday, June 15, 2026
DISCLAIMER: AI-generated signals are for informational purposes only. All trading and investment decisions are solely the user's responsibility.|Past performance does not guarantee future results. Trade at your own risk.|Anadi Algo is not a SEBI-registered advisor. Consult a qualified financial advisor before acting on any recommendation.|DISCLAIMER: AI-generated signals are for informational purposes only. All trading and investment decisions are solely the user's responsibility.|Past performance does not guarantee future results. Trade at your own risk.|Anadi Algo is not a SEBI-registered advisor. Consult a qualified financial advisor before acting on any recommendation.|
Stock Landing|14 matching stories

GRANULES Share Price, Latest News & Sentiment

Latest AI-analyzed news for GRANULES, along with saved share-price context, sentiment, quarterly filing summary, and related names in one page.

Stock Coverage Hub

GRANULES News Today

Widely covered stock

The broader market is currently exhibiting a bearish short-term bias, with Nifty facing resistance. This makes stock-specific recommendations crucial for identifying pockets of strength.

Coverage
14
recent stories
Sources
4
distinct publishers
Bias Split
8 bullish / 3 bearish
3 neutral stories
Window
71d
recent coverage span
Saved Quote Snapshot

GRANULES

Last Updated
23 May 2026
Price
NA
NA
52W Range
NA - NA
exchange snapshot
PE / VWAP
PE NA
VWAP NA
Trend Read
bullish
Bullish stack · EMA 5 > 9 > 21 > 50
Business Context
Industry: NA
Sector Trail: NA
Listing Date: NA
Market Structure
F&O Eligible: No
Indices: NA
Snapshot Source: mcp+nse
Quarterly Read

Quarter ended 31 Dec 2024

Consolidated results
What This Quarter Says

Granules reported its latest financial results. The company made ₹1137.69 crore in sales and ₹117.6 crore in profit. This information is on record, and we don't have past data to compare it with.

Revenue
Rs 1,138 cr
up 35.1% vs previous filing
Profit
Rs 117.6 cr
up 30.5% vs previous filing
EPS / Finance Cost
EPS 4.85
Finance cost Rs 26.57 cr
Filing Context
Filed 24 Jan 2025, 8:16 pm
Figures are taken from the saved exchange filing, not from a live request.
Quick Reader Notes
  • Revenue this quarter: Rs 1,138 cr, up 35.1% vs previous filing.
  • Profit this quarter: Rs 117.6 cr, up 30.5% vs previous filing.
  • EPS gives a quick sense of per-share earnings: 4.85.
How To Read This

Treat this block as a saved quarter snapshot. First see whether revenue and profit are improving, then read the latest news below to judge whether recent headlines support that trend or work against it.

GRANULES FAQ

Why is GRANULES in the news right now?

GRANULES has appeared across 14 recent stories from 4 sources, which usually means there is a real flow of fresh headlines rather than a single isolated mention.

Is GRANULES coverage bullish or bearish right now?

GRANULES coverage is currently leaning bullish, with 8 bullish, 3 bearish, and 3 neutral analyzed stories in the recent window.

Which themes are moving with GRANULES?

Recent GRANULES coverage is clustering around Pharmaceuticals and Financial Services. Related names showing up alongside GRANULES include AUROPHARMA, DIVISLAB, LAURUSLABS.

How should I use this GRANULES news page?

Use this page as a coverage hub for GRANULES: start with the latest headlines, then check the dominant themes, related names, and saved market context before you form a trade or watchlist view.

Workflow View

Use GRANULES coverage to build a cleaner watchlist.

A stock page is most useful when it helps you slow down, compare headlines, and separate one-off noise from a repeatable setup.

This is here if you want to go deeper, not as a push.Explore Anadi
Focus on individual stock momentum and technical breakouts in the recommended names, maintaining strict risk management given the cautious overall market.|Quick check: ANGELONE bullish bias (+7.3% 1d), TATATECH bullish bias (overbought).

Latest GRANULES Stock Coverage

Maintain a cautious stance on Indian export-oriented stocks with significant Middle East exposure; look for short-term opportunities in sectors less reliant on this trade route, while keeping an eye on crude oil price movements.|Quick check: GRANULES bullish bias (overbought), LT neutral (+0.0% 1d).
Market has likely priced in the headline, so trade GRANULES only on confirmation of clean follow-up with upside limited to verified US export normalization; otherwise stay underweight and use defensive risk discipline.
Treat GRANULES as a hold/watchlist setup for now: reduce/new positions only after objective US-FDA follow-through (clean inspection updates, no fresh adverse notices), otherwise keep exposure under control despite the company’s announced fixes.
Given the article's age, consider these recommendations as historical expert sentiment; evaluate current technicals and fundamentals before making any trading decisions.
Given the article's age, the market has likely priced in these recommendations; focus on current technicals and broader market momentum for fresh entry points.
Market has likely priced this in, but watch for specific company announcements on benefiting from these measures; positive for export-oriented stocks in affected sectors.
Market has likely priced in these specific recommendations; focus on the broader market sentiment and sector trends that influenced these calls.
Given the article's age, the market has likely priced in some of this, but monitor Q4 and Q1 results of API manufacturers for sustained margin pressure; consider short-term bearish bias on API-heavy pharma stocks.
Market has likely priced this in; however, monitor companies with significant export exposure to South Asia for sustained growth opportunities.
Bullish for Indian API manufacturers; consider long positions in key domestic players benefiting from export growth and PLI schemes.